Safety and efficacy of continuous subcutaneous foslevodopa-foscarbidopa in patients with advanced Parkinson's disease: a randomised, double-blind, active-controlled, phase 3 trial

Autor: Soileau, Michael J *, Aldred, Jason, Budur, Kumar, Fisseha, Nahome, Fung, Victor SC, Jeong, Anna, Kimber, Thomas E, Klos, Kevin, Litvan, Irene, O'Neill, Daniel, Robieson, Weining Z, Spindler, Meredith A, Standaert, David G, Talapala, Saritha, Vaou, Eleni Okeanis, Zheng, Hui, Facheris, Maurizio F, Hauser, Robert A
Zdroj: In The Lancet Neurology December 2022 21(12):1099-1109
Databáze: ScienceDirect